BIO-RAD PAPER DESCRIBES THE EFFECT OF RNA DEGRADATION ON DATA QUALITY IN QUANTITATIVE PCR AND MICROARRAY EXPERIMENTS

 

 

HERCULES, CA – January 30, 2008 Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the availability of a technical paper (bulletin 5452A) that describes the effect of RNA degradation on data quality in quantitative PCR and microarray experiments. The paper describes using automated electrophoresis to determine RNA quality prior to gene expression analysis.

 

Quantitative expression levels, when determined by qPCR, decrease as RNA becomes increasingly degraded. This can lead to erroneous conclusions regarding the levels of gene expression when comparing samples that are degraded to different extents. Genes with high levels of expression can still be characterized but degradation compromises the ability to detect differences in genes that are expressed at low levels.

 

Bio-Rad’s Experion™ automated electrophoresis system is an effective method to determine the quality and quantity of RNA in gene expression analysis experiments. The Experion system accurately quantitates and evaluates the integrity of samples using as little as 25 ng total RNA, which is several hundred times less material than that required for gel electrophoresis. Once RNA quantity and quality have been established, a researcher can determine whether or not to move forward with additional experiments, knowing to what degree the results may be compromised.

 

The six-page paper provides a detailed introduction, methods description, results, and a discussion, supported by numerous graphs, tables, figures, and electropherograms.

 

Availability

Bulletin 5452A is available either from a local Bio-Rad sales office or it may be downloaded at www.bio-rad.com.

 

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,300 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com.

 

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

 

NOTE TO THE EDITOR:

For an html link to this news please visit the following URL: http://www.alchymiacomm.com/NewsReleasesPhotography.html

Sales information may be obtained by calling a Bio-Rad sales office at 1-800-424-6723. Please DO NOT use editor contact or corporate telephone numbers.

Information in this release applies specifically to products available in the United States. Product availability and specifications may vary in non‑U.S. markets.

If you choose to review this item, your readers will receive the quickest response to their inquiries by e‑mailing them to lsg.orders.us@bio-rad.com or by calling 1-800-424-6723.

For more information, please contact:

Mary Grace Brubacher

Bio-Rad Laboratories, Inc.

510-741-5347

MaryGrace_Brubacher@bio-rad.com

 

Doug Forsyth

Alchymia Communications(r) LLC

541-482-8744

df@alchymiacomm.com